NeuroPace Inc warns less than 5 percent seizure reduction when medications fail twice

NeuroPace Inc warns less than 5 percent seizure reduction when medications fail twice
NeuroPace Inc warns on drug limits

NeuroPace Inc announces that patients who have failed two or more seizure medications face less than a 5 percent chance of further seizure reduction if they continue with medication alone.

The company promotes its RNS System as a different treatment option and encourages patients to use its online quiz to determine their suitability. NeuroPace Inc also provides safety information for those interested in exploring this alternative approach.

NeuroPace has previously encouraged people with uncontrolled seizures to assess their eligibility for the RNS System via an online quiz. The company also presented results from its NAUTILUS Study, which reported advances in neuromodulation for drug-resistant IGE at the 2026 AAN meeting earlier this year. These initiatives underscore NeuroPace’s ongoing focus on alternative therapies for patients with limited medication options.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.